Waddell et al. [18] assessed familial breast tumours from 75 patients who carried pathogenic variants in BRCA1 or BRCA2, or were BRCAx, to determine molecular heterogeneity between and within each subgroup. This evidence concerns the gene BRCA2 and breast neoplasm.